Care Pathway for Health Care Providers
Perinatal mood and anxiety disorders (PMAD) are a common complication during pregnancy and the first year after delivery. Health Care providers play an essential role in identifying PMAD and facilitating timely access to pharmacotherapy and/or psychosocial support and treatment1.

Screening Tools
- Patients with risk factors for mood and anxiety disorders should be screened at least once during pregnancy and once during the postpartum period using a validated screening tool (i.e. EPDS, PHQ0, GAD-7)1.
- Screening should be complemented with a clearly defined and locally tailored referral process1.
Additional Resources
General Considerations for PMAD Treatment |
Recommendations for treatment are outlined in the Care Pathway Document. General considerations for PMAD treatment include:
|
Patient Handouts and Resources |
|
Clinical References |
|
Citations
[1] Shea, A., Jumah, N. A., Forte, M., Cantin, C., Bayrampour, H., Butler, K., Francoeur, D., Green, C., & Cook, J.(2024). Guideline No. 454: Identification and treatment of perinatal mood and anxiety disorders. Journal of Obstetrics and Gynaecology Canada, 46(10), 102696. https://doi.org/10.1016/j.jogc.2024.102696
[2] Vigod et al, S. N. (2025). Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders. The Canadian Journal of Psychiatry. https://www.canmat.org/2025/02/12/available-now-canmat-2024-guidelines-for-perinatal-mood-anxiety-and-related-disorders-and-accompanying-patient-and-family-guide/